<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:Verdana;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
p.preheader-container, li.preheader-container, div.preheader-container
{mso-style-name:preheader-container;
margin:0cm;
margin-bottom:.0001pt;
mso-line-height-alt:.75pt;
font-size:1.0pt;
font-family:"Times New Roman","serif";
display:none;}
span.greeting-tag
{mso-style-name:greeting-tag;}
span.footer-column
{mso-style-name:footer-column;}
span.footer-mobile-hidden
{mso-style-name:footer-mobile-hidden;}
span.EmailStyle22
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:1981834;
mso-list-template-ids:707307146;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1
{mso-list-id:20862694;
mso-list-template-ids:-146272878;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2
{mso-list-id:56588976;
mso-list-template-ids:611103630;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3
{mso-list-id:94642344;
mso-list-template-ids:413839380;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4
{mso-list-id:249315151;
mso-list-template-ids:-574721876;}
@list l4:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5
{mso-list-id:307563327;
mso-list-template-ids:822014426;}
@list l5:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l6
{mso-list-id:308364506;
mso-list-template-ids:1474486604;}
@list l6:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l7
{mso-list-id:354230320;
mso-list-template-ids:160442236;}
@list l7:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l8
{mso-list-id:380595793;
mso-list-template-ids:-875132948;}
@list l8:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l9
{mso-list-id:534273301;
mso-list-template-ids:2074089576;}
@list l9:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l10
{mso-list-id:830296120;
mso-list-template-ids:-1987831310;}
@list l10:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l11
{mso-list-id:853764329;
mso-list-template-ids:-558755612;}
@list l11:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l12
{mso-list-id:965502599;
mso-list-template-ids:354087892;}
@list l12:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l13
{mso-list-id:1014726451;
mso-list-template-ids:1537013094;}
@list l13:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l14
{mso-list-id:1132868263;
mso-list-template-ids:-1203072780;}
@list l14:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l15
{mso-list-id:1157570310;
mso-list-template-ids:-1137699620;}
@list l15:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l16
{mso-list-id:1250650351;
mso-list-template-ids:-1038188738;}
@list l16:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l17
{mso-list-id:1362434273;
mso-list-template-ids:1619964062;}
@list l17:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l18
{mso-list-id:1421759889;
mso-list-template-ids:-1029255188;}
@list l18:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l19
{mso-list-id:1477986988;
mso-list-template-ids:-576813072;}
@list l19:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l20
{mso-list-id:1575430637;
mso-list-template-ids:1280233290;}
@list l20:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l21
{mso-list-id:1649161850;
mso-list-template-ids:1557980528;}
@list l21:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l22
{mso-list-id:2116944030;
mso-list-template-ids:-1607858458;}
@list l22:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
ol
{margin-bottom:0cm;}
ul
{margin-bottom:0cm;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body bgcolor=whitesmoke lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>I subscribe to the UsTOO e-newsletter.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>UsToo is likely the largest Prostate Cancer support organization in the US.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Below is the latest note from UsToo.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Rather than relying on me to see interesting articles & forwarding them to the group, you may wish (as part of being your own advocate) to subscribe.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>In the meantime, scroll down thru the note below.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Take care,<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>From:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> Chuck Strand, CEO, Us TOO International [mailto:chucks@ustoo.org] <br><b>Sent:</b> June 21, 2019 4:38 PM<br><b>To:</b> glen46nor@gmail.com<br><b>Subject:</b> Prostate Cancer News You Can Use<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td style='padding:0cm 0cm 0cm 0cm'><div><p class=MsoNormal align=center style='text-align:center;mso-line-height-alt:.75pt'><span style='font-size:1.0pt'><img id="_x0000_i1025" src="http://r20.rs6.net/on.jsp?ca=0e0aa404-71d8-40b2-89bd-1a312acae9a5&a=1127669815285&c=1bc05c4a-6b5e-11e9-96cd-d4ae527b6fcc&ch=1bc4ebc0-6b5e-11e9-96cd-d4ae527b6fcc"><o:p></o:p></span></p></div></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><div><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:whitesmoke;border-collapse:collapse;min-width: 100%'><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=612 style='width:459.0pt;border-collapse:collapse'><tr><td valign=top style='padding:11.25pt 3.75pt 11.25pt 3.75pt'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td valign=top style='background:black;padding:.75pt .75pt .75pt .75pt'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:black;border-collapse:collapse'><tr><td valign=top style='background:white;padding:0cm 0cm 0cm 0cm'><div><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td width="100%" valign=top style='width:100.0%;padding:0cm 0cm 0cm 0cm'><div><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td valign=top style='padding:7.5pt 0cm 7.5pt 0cm'><div><p class=MsoNormal align=center style='text-align:center'><img width=177 id="_x0000_i1026" src="https://files.constantcontact.com/5f7db5e8601/cbaea20a-28e5-47c3-b92c-99ff3917a167.jpg"><o:p></o:p></p></div></td></tr></table></div></td></tr></table></div><p class=MsoNormal align=center style='text-align:center'><o:p> </o:p></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width: 100%'><tr><td width="100%" valign=top style='width:100.0%;padding:0cm 0cm 0cm 0cm;word-wrap: break-word'><div><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;word-wrap: break-word'><tr><td valign=top style='padding:7.5pt 15.0pt 7.5pt 15.0pt'><div><div><p class=MsoNormal align=center style='text-align:center'><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS48Nc-c4H6fSDrOdzcW5b3Vhfh1WauoIry4W5Bh2K5CIp8IdsbPz16xcoS60ofWfR5TNDQmjE5N9rhxe2BPG0oA=&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw==" target="_blank"><span style='font-size:9.0pt;color:#0078C1'>www.ustoo.org</span></a> </span><span style='font-family:"Arial","sans-serif";color:#141414'> |</span><span style='font-family:"Arial","sans-serif";color:#333333'> </span><span style='font-size:9.0pt;font-family:"Arial","sans-serif";color:#333333'> </span><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS5Eb_W96da_SblEp3AFvsU6RX95znpEnXHYubcOs6Vb4jxZ2FgdZdpIw9IZYkJtYR8mIWHKjq8XYW1SfMWILpFfKkSWpaNvVHqy_fjZWbsoiauCC2xCqnhKjjCNZCcfxQM0yvNuvYeYN&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw==" target="_blank"><span style='font-size:9.0pt;color:#0078C1'>Donate</span></a> </span><span style='font-family:"Arial","sans-serif";color:#141414'> |</span><span style='font-family:"Arial","sans-serif";color:#333333'> </span><u><span style='font-size:9.0pt;font-family:"Arial","sans-serif";color:#1E7CE8'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS5NNRduniZU_wJbEMFLETihKLCrwt6halYuV6luLLG4e735LS8lJctu-h94R5YoHq9XE5309O5Y1Z0eawZPk0E6SKAgT5Fl8ag==&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw=="><span style='color:#1E7CE8'>View in Browser</span></a></span></u><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p><p class=MsoNormal align=right style='text-align:right'><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p><p class=MsoNormal align=center style='text-align:center'><i><span style='font-size:9.0pt;font-family:"Arial","sans-serif";color:#333333'>Made possible by a charitable contribution from </span></i><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS5Eb_W96da_SKsNHyDSbhZ2QoahMpTk2MoOUc7CaJB8YsyOAucCWQfbDpsGJcAPLgm6_ab4cUJvV21-KisgxIn4=&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw==" target="_blank"><b><i><span style='font-size:9.0pt;color:#0078C1'>Bayer</span></i></b></a> <o:p></o:p></span></p><p class=MsoNormal align=center style='text-align:center'><i><span style='font-size:9.0pt;font-family:"Arial","sans-serif";color:#0078C1'>Navigation Tip: Click on blue text that’s italicized, underlined and in bold for link to more information.</span></i><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p><p class=MsoNormal align=center style='text-align:center'><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p><div><p class=MsoNormal><span class=greeting-tag><span style='font-family:"Arial","sans-serif";color:black'>Hello Glen,</span></span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>We hope this note finds you doing well on this first day of the summer season! </span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>We’re pleased to provide you with some of the latest <b>Prostate Cancer News You Can Use</b>. In addition to the following updates and information that may be of interest to you, the titles of prostate cancer news articles are listed below along with a link to the Us TOO web page that provides access to the full text for each article.</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>Join us in welcoming <b>Development Director James Hutson</b> to the staff at Us TOO! The impact of his work will help us expand the scope of services and resources that we can provide to the prostate cancer community at no charge.</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>Registration is now open at </span><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS1__kSLZOwqVN35QX5_cmqYiWqUW9q0HESs4YXIPw6BMN9LjrFQdF77z9t9CyJ-4HPHUyj6Vl1RnbMRHkdPvwyhlTqi9__GfNnfxHiN3gXFe&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw==" target="_blank"><b><i><span style='color:#005487'>www.seablueprostatewalk.org</span></i></b></a></span><span style='font-family:"Arial","sans-serif";color:black'> for the <b>15th Annual SEA Blue Chicago Prostate Cancer Walk & Run</b>, which will take place on September 15th in beautiful Lincoln Park. </span><b><span style='font-family:"Arial","sans-serif";color:#005487'>SEA</span></b><span style='font-family:"Arial","sans-serif";color:black'> is an acronym for </span><b><span style='font-family:"Arial","sans-serif";color:#005487'>S</span></b><span style='font-family:"Arial","sans-serif";color:black'>upport, </span><b><span style='font-family:"Arial","sans-serif";color:#005487'>E</span></b><span style='font-family:"Arial","sans-serif";color:black'>ducate and </span><b><span style='font-family:"Arial","sans-serif";color:#005487'>A</span></b><span style='font-family:"Arial","sans-serif";color:black'>dvocate; and blue is to prostate cancer as pink is to breast cancer. Attend in person or register as a virtual mover at no charge if you will not attend in person and want to help fundraise (even from a remote location). </span><b><span style='font-family:"Arial","sans-serif";color:#005487'>For a glimpse into what makes this event so special for so many people, </span></b><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS6FHXE06-YRTUtT7J_2ANS5M1Q4qrOp7sh766DsJJpsVDbBW9d8e2NpSxBkwk-fyEuEn1nfiSRj9bGXfD1RDh4hdKMiZJGhNwExgQUiC_VA9nxa6vq2dZYOLWe00VphUEHmfkTNeBrm1_Q4fA6Are9Q=&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw==" target="_blank"><b><i><span style='color:#005487'>check out the video</span></i></b></a></span><b><span style='font-family:"Arial","sans-serif";color:#005487'>.</span></b><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><b><span style='font-family:"Arial","sans-serif";color:black'>If you are the wife or female partner of a man with prostate cancer, we invite you to join a conference call to connect with other women facing similar challenges</span></b><span style='font-family:"Arial","sans-serif";color:black'>. Because prostate cancer is a couple's disease, the woman is often subject to her own concerns in addition to those she shares with her partner. <b><i>A Forum for Her</i></b> is an ongoing series of conference calls and invitation-only Facebook group that provides women with important peer-to-peer support. For more information, </span><b><span style='font-family:"Arial","sans-serif";color:#005487'>visit </span></b><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS45N3xzSQBTi-Zw4HDyhxvAssnHkCTicOz23OI-OrVz-ducnr81nV4_C-GXtbrYFlAY9lwBm0oog-112Ibg8k4B4OH-x38nM7Ps6GK5eeNNb&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw==" target="_blank"><b><i><span style='color:#005487'>ustoo.org/aforumforher</span></i></b></a></span><b><span style='font-family:"Arial","sans-serif";color:#005487'>. </span></b><span style='font-family:"Arial","sans-serif";color:black'>To register, email <a href="mailto:terril@ustoo.org">terril@ustoo.org</a> or call 336-842-3578. </span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>Based on the success of <b><i>A Forum for Her</i></b> and requests for a similar service for the gay community, we are pleased to introduce </span><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS5NNRduniZU_ZjY1vfVfMk1vTGQAv6qk_tM8VF3_ifWVtLldnhYl01mFO5Fpz2cQ5EstDC1nyd_9ju91LGRiOpOPbQ9aQsR_qPTaqXe8wf6a&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw==" target="_blank"><b><i><span style='color:#005487'>A Prostate Cancer Forum for Gay Men and Their Partners</span></i></b></a></span><span style='font-family:"Arial","sans-serif";color:black'>. This ongoing conference call series from Us TOO will provide gay men and their partners with important peer-to-peer support. Calls will begin in late June. <b>To reserve your spot and get the call-in information, email </b></span><span style='font-family:"Arial","sans-serif";color:#333333'><a href="mailto:terril@ustoo.org" target="_blank"><b><span style='color:black'>terril@ustoo.org</span></b></a></span><b><span style='font-family:"Arial","sans-serif";color:black'> or call 336-842-3578.</span></b><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>Prostate cancer support groups provide a valuable opportunity to connect with others for education, support and perspective on managing every aspect of the disease – from testing to active surveillance, treatment options and side effect management. <b>Us TOO has a network of more than 200 support groups in the U.S. and abroad</b>. We thank all of the support group leaders and encourage men diagnosed with prostate cancer </span><b><span style='font-family:"Arial","sans-serif";color:#005487'>to find an Us TOO support group at </span></b><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS4VAzyHsLR1y6f90nBOa7B-QC674rdfvWOeT7sCHqPLG8q1rorKhSS28i5qionkExR6YSXv7zM0ilHSSSdpzfm6gccA0Wh2xlHNE6FkvECMFhAL8HD_g4ng=&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw==" target="_blank"><b><i><span style='color:#005487'>ustoo.org/Support-Group-Near-You</span></i></b></a></span><b><span style='font-family:"Arial","sans-serif";color:#005487'>.</span></b><span style='font-family:"Arial","sans-serif";color:black'> </span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>No support group in your immediate area? Us TOO partners with <b>Answer Cancer Foundation, the first virtual, real time, call-in peer-to-peer support group platform</b> providing online access from a computer, mobile device or telephone. In addition to calls each month focused on high-risk/recurrent/advanced disease, low-risk/intermediate prostate cancer, AnCan is now hosting an <b>Active Surveillance Prostate Cancer virtual support group. Calls will be on the first Wednesday of every month at 8:00 pm Eastern</b>. </span><b><span style='font-family:"Arial","sans-serif";color:#005487'>Find details at: </span></b><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS2pWsER9EsGk-sYHQ5gqqvdIMYQgMuDy2MRuqbDtvBPo81qZko1RdnJnAHQqstqzGmah-3tdnJhBFilyZgHQRSYa2eXMFtrFb2P47Y3vMT0i&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw==" target="_blank"><b><i><span style='color:#005487'>ancan.org/prostate-cancer</span></i></b></a></span><b><i><span style='font-family:"Arial","sans-serif";color:#005487'>.</span></i></b><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><b><span style='font-family:"Arial","sans-serif";color:black'>NEWS YOU CAN USE ARTICLES:</span></b><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>Please note that the content below lists only the title of the article rather than a direct link to the content. </span><b><span style='font-family:"Arial","sans-serif";color:#005487'>For access to the full article </span></b><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MSzoxM1MF0W8yBynvQFUNKsXlP7Vd3kjyp6aicoFAstuIGys5m_SMEr0QBFkWX7YKdRFLz82wDOdhop2uxL9uDJAVZEybHslWnYEXsmk8zPGIOxCEV1caPIs=&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw==" target="_blank"><b><i><span style='color:#005487'>CLICK HERE</span></i></b></a></span><span style='font-family:"Arial","sans-serif";color:black'>.</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l12 level1 lfo1'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Men who choose <b>active surveillance</b> for early prostate cancer often don’t follow monitoring rules <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l1 level1 lfo2'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Men choose <b>active surveillance</b> for early age prostate cancer instead of treatment <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l8 level1 lfo3'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Black men less likely than nonblack men to adopt <b>active surveillance</b> <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l4 level1 lfo4'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><b><span style='font-family:"Arial","sans-serif";color:black'>MRI, ultrasound</span></b><span style='font-family:"Arial","sans-serif";color:black'> more accurate in locating prostate cancer, study says <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l0 level1 lfo5'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><b><span style='font-family:"Arial","sans-serif";color:black'>Biomarker</span></b><span style='font-family:"Arial","sans-serif";color:black'> may help identify men with prostate cancer at greater risk of tumor metastasis <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l9 level1 lfo6'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>New insights into <b>treatment targets</b> for men with advanced prostate cancers <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l15 level1 lfo7'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Study finds how prostate <b>cancer cells mimic bone</b> when they metastasize <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l21 level1 lfo8'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><b><span style='font-family:"Arial","sans-serif";color:black'>Enzalutamide</span></b><span style='font-family:"Arial","sans-serif";color:black'> improves survival for men with metastatic hormone-sensitive prostate cancer <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l3 level1 lfo9'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>ERLEADA® <b>apalutamide</b> Significantly Improved Overall Survival OS and Radiographic Progression-Free Survival rPFS in Patients with Metastatic Castration-Sensitive Prostate Cancer mCSPC <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l11 level1 lfo10'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>New Findings from Monash University in Prostate Cancer Provides New Insights (The <b>Influence of Brca2</b> Mutation On Localized Prostate Cancer) <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l20 level1 lfo11'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Study Findings from Duke University Provide New Insights into Prostate Cancer (An Update of Research Evidence On <b>Nutrition and Prostate Cancer</b>) <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l16 level1 lfo12'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Researchers from University of Western Ontario Provide Details of New Studies and Findings in the Area of Prostate Cancer (A novel approach for assessment of prostate cancer aggressiveness using survivin-driven <b>tumour-activatable minicircles</b>) <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l22 level1 lfo13'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Researchers from University of Illinois - Chicago Report on Findings in Prostate Cancer (<b>Role of Estrogen</b> in Androgen-Induced Prostate Carcinogenesis in NBL Rats) <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l10 level1 lfo14'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Researchers from St. Orsola Marcello Malpighi Hospital Discuss Findings in Prostate Cancer (The <b>Human Microbiota</b> and Prostate Cancer: Friend or Foe?) <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l14 level1 lfo15'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Community pharmacies may improve <b>cardiovascular health</b> for prostate patients <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l2 level1 lfo16'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Reports Outline Prostate Cancer Study Findings from National Cancer Institute (<b>Prostate Imaging</b> Reporting and Data System Version 2 for Mri of Prostate Cancer: Can We Do Better?) <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l17 level1 lfo17'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Studies from Spanish National Cancer Research Center in the Area of Prostate Cancer Reported (<b>Brca2 </b>and Other Ddr Genes In Prostate Cancer) <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l5 level1 lfo18'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Researchers from University of Pennsylvania Discuss Findings in Prostate Cancer (Variations In Patterns of Concurrent <b>Androgen Deprivation Therapy</b> Use Based On Dose Escalation With External Beam Radiotherapy Vs. Brachytherapy Boost for Prostate ...) <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l18 level1 lfo19'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Study shows more effective method for <b>detecting prostate cancer</b> <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l7 level1 lfo20'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>New Prostate Cancer Findings Has Been Reported by Researchers at University of Pittsburgh Medical Center (<b>Multiparametric Magnetic Resonance Imaging</b> Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance) <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l13 level1 lfo21'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>Researchers from University of Kentucky Describe Findings in Prostatectomy (Examining and <b>Understanding Value</b>: the Impact of Preoperative Characteristics, Intraoperative Variables, and Postoperative Complications On Cost of Robot-assisted ...) <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l6 level1 lfo22'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:black'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span style='font-family:"Arial","sans-serif";color:black'>PatientPoint and Us TOO International Launch <b>Prostate Cancer Education Campaign</b> <o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><b><span style='font-family:"Arial","sans-serif";color:black'>MORE NEWS & CLINICAL TRIALS:</span></b><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>Results from the <b>TITAN study</b>, announced at ASCO 2019, showed that ERLEADA® (apalutamide) significantly improved overall survival (OS) and radiographic progression-free survival (rPFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC). </span><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS5NNRduniZU_P6Mh-I4QN11OaEVJKkWfxUJW1izOUCCeYM5Au6WDz46s-HW_pNkaumSKxRHeaEZlmeTvzYdAwqTxtN1VHHJO_KMn5HQPkulIG1liBchby0pbwd8nlJJ1WdsmPI9f1qQMtUOo-Vk3TtxZM-xlYrPqAbxHE5El-sLboy95T1Lbm0iRSs0J5plUiJRGTrw4yZHoxKq3rCK5WX4T4m9ZcnHtRLnaXNtWwp2hSyDzjdzg67R8szxatvi6oZtvNNNtiWGTLdeZwIYh5aPl2G96o1qVi_dPFYz1CzGhtfQ3pryPA2ltx-Y1YHQmKMTr_D8DSd_c&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw==" target="_blank"><b><i><span style='color:#005487'>CLICK HERE</span></i></b></a></span><b><i><span style='font-family:"Arial","sans-serif";color:#005487'> to read the press release.</span></i></b><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'> </span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>Men with <b>metastatic castration-resistant prostate cancer</b> are invited to consider enrollment in one of two international, Pfizer-sponsored studies of talazoparib, a PARP inhibitor:</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l19 level1 lfo23'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><b><span style='font-family:"Arial","sans-serif";color:black'>TALAPRO-1:</span></b><span style='font-family:"Arial","sans-serif";color:black'> A phase 2, open-label study of talazoparib in men with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal therapy (NHT) </span><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS5NNRduniZU_f69_dol5NQ1Fle96T4kWddo4_ehMiXJwa4OyiCKMFS5x0a6-2k0F_bYpCpXlxlVBNOJtpo1NQmgNlno8Usuw8Ayfx7rEMFUMq48ebxyfYVefvZ1OA-fEaMwHCGog2ftyiyJdPObxkJcfz-Gyvx__DVLsZMrfabqj&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw==" target="_blank"><b><i><span style='color:#005487'>NCT03148795</span></i></b></a></span><span style='font-family:"Arial","sans-serif";color:black'> </span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l19 level1 lfo23'><![if !supportLists]><span style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><b><span style='font-family:"Arial","sans-serif";color:black'>TALAPRO-2:</span></b><span style='font-family:"Arial","sans-serif";color:black'> A phase 3, randomized, double-blind, placebo-controlled study of talazoparib with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) </span><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS5NNRduniZU_7hDzzq6Z98ivZYsIDlDZDpe9EgQUb2glPwonJvMDbsMPCOXQhLNkrQYc7-rvJvwNgWtu3VjX226t81JP5dzYljWXfBB8Ol9l-enXMGzXUlN6yFQZZ3b4iL8ZjAQtm3FcmA0I7znW842wCrVTBTb1qvQTXdQp3aTK&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw==" target="_blank"><b><i><span style='color:#005487'>NCT03395197</span></i></b></a></span><span style='font-family:"Arial","sans-serif";color:black'> </span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS5NNRduniZU_VKxzJbD8cyQCklktTBH_wSQkO7xilnx63B4etQB00fhGyuBIZfDeeGCks55A_1yxERD9qOo6senmO9czHJk0g0Q2-CrEStjK&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw==" target="_blank"><b><i><span style='color:#005487'>CLICK HERE</span></i></b></a></span><b><i><span style='font-family:"Arial","sans-serif";color:#005487'> for an overview of these studies in patient-friendly language.</span></i></b><span style='font-family:"Arial","sans-serif";color:black'> </span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>An ASCO 2019 abstract provides data on 221 African American (AA) patients and 1,649 Caucasian (CAU) <b>patients who received sipuleucel-T</b>. In terms of all patients, the median overall survival (OS) for AA patients was 35.2 months and the median OS for CAU patients was 25.8 months. </span><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS5NNRduniZU_HmUy8QSqUG2sfVs5snRhtQ-foRk3H4fYSCfJu_Z0r1DFpkHAGCuuu5QLj8dxPdnz8GRlvJV8-ED_frrhRhlHOZ9SsMLOLMTSwlJCRu2fr_SgkDKrfE3blSw0NSxQlph-8uXVsLyqdMNjbZ5ql_UywGSwdEOOPGBL5opd02VdOOaN71TWZIKXEA-0fHB2WN6ogMKf3yv6UlIb8KuUg2V9_E95lTRCYP-LIDsFbNM3sAbQ4UBN895OJPxRpdIfK-xcP6AeNbwzCyj-guRwsjK4I5JcZuuUhZNAl83z9lHSueCenO_jHk6OGOrOoCbSK1cKab97KlKffKVZgw89i5avpUAI7GwKGqEEKuQ_rIa4R_HbVbhvyjiqI3AtpOE6huRGHQLBS8hadsE=&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw==" target="_blank"><b><i><span style='color:#005487'>CLICK HERE</span></i></b></a></span><b><i><span style='font-family:"Arial","sans-serif";color:#005487'> to read more.</span></i></b><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>Dendreon is currently enrolling men in the <b>ProVent clinical trial</b>. This new investigational study will evaluate the effectiveness of sipuleucel-T in <b>reducing disease progression</b> in men with lower-risk prostate cancer who are candidates for active surveillance. </span><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS_-IG8MKbbLmd6tmEdhL4DCgRI0jVkQ1WEHDUjMazSSt8jAF0uW72G9W3aHw9AyQbUxG3PUWqRQaF7qOsGgnyz7HZK69RdKCxOQEIgSi2ljr4WRhRMm1Uftje1dsweyyxZvaEWIp98Yx&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw==" target="_blank"><b><i><span style='color:#005487'>CLICK HERE</span></i></b></a></span><b><span style='font-family:"Arial","sans-serif";color:#005487'> to learn more.</span></b><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS45N3xzSQBTits5wq4jqfrflTqfcctJIjJ-95C5xjl3c2UXOP42Q8WWHyQWD23hjg-QawK5KfDdanl8CRxQ9Hgvhy5EVDe3M5w==&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw==" target="_blank"><b><i><span style='color:#005487'>The Metastatic Prostate Cancer Project</span></i></b></a></span><b><i><span style='font-family:"Arial","sans-serif";color:#005487'> is a nationwide genomic research study for men with metastatic and/or advanced prostate cancer.</span></i></b><span style='font-family:"Arial","sans-serif";color:black'> Patients can join online and participate by sharing their medical information and samples. The project’s goal is to release new data to help researchers better understand metastatic and advanced prostate cancer, and accelerate discoveries. </span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS6sMhxZeKPsdCJO-dv4m2d63Atdq5YmrLJDdurnDHsWJDxwCBxY8vzjxQTUG1VCbtZZMPHK5Bq5vit9S0pOJvjF4n4DKa93-6g==&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw==" target="_blank"><b><i><span style='color:#005487'>IRONMAN</span></i></b></a></span><b><i><span style='font-family:"Arial","sans-serif";color:#005487'> is a registry recruiting 5,000 men with advanced prostate cancer from 9 countries.</span></i></b><span style='font-family:"Arial","sans-serif";color:black'> More than 366,000 men die of prostate cancer globally every year. Research on a man's type of prostate cancer, treatment and side effects will help inform what causes prostate cancer, how to stop or slow its progression, and how to provide the best possible care to enable men to maximize their quality of life. </span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>Take care and enjoy the summer breezes and extra sunshine! Since <b>June is Men’s Health Month</b>, it's a great time to talk to friends and family about the importance of prostate cancer awareness and education. Watch for the July 2019 issue of the Us TOO Hot SHEET newsletter next week; and let us know how we can help provide you with educational resources, support services and personal connections to others in the prostate cancer community.</span><span style='font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'></span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:black'>All the best,</span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div></div></div></td></tr></table></div></td></tr></table></div><p class=MsoNormal align=center style='text-align:center'><o:p> </o:p></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width: 100%'><tr><td width="100%" valign=top style='width:100.0%;padding:0cm 0cm 0cm 0cm;word-wrap: break-word'><div><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;word-wrap: break-word'><tr><td valign=top style='padding:7.5pt 15.0pt 7.5pt 15.0pt'><div><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left style='border-collapse:collapse;margin-right:3.5pt'><tr style='height:.75pt'><td valign=top style='padding:0cm 0cm 0cm 0cm;height:.75pt'><div><p class=MsoNormal align=center style='text-align:center'><img border=0 width=241 id="_x0000_i1027" src="http://files.constantcontact.com/5f7db5e8601/285ae02b-4062-49c5-94b6-deb06cb11629.jpg"><o:p></o:p></p></div></td><td width=15 valign=top style='width:11.25pt;padding:0cm 0cm 0cm 0cm;height:.75pt'><p class=MsoNormal align=center style='text-align:center;mso-line-height-alt:.75pt'><img border=0 width=15 height=1 id="_x0000_i1028" src="https://imgssl.constantcontact.com/letters/images/sys/S.gif"><o:p></o:p></p></td></tr><tr style='height:.75pt'><td valign=top style='padding:0cm 0cm 0cm 0cm;height:.75pt'><p class=MsoNormal align=center style='text-align:center;mso-line-height-alt:3.75pt'><img border=0 width=1 height=5 id="_x0000_i1029" src="https://imgssl.constantcontact.com/letters/images/sys/S.gif"><o:p></o:p></p></td><td width=5 valign=top style='width:3.75pt;padding:0cm 0cm 0cm 0cm;height:.75pt'><p class=MsoNormal align=center style='text-align:center;mso-line-height-alt:.75pt'><img border=0 width=5 height=1 id="_x0000_i1030" src="https://imgssl.constantcontact.com/letters/images/sys/S.gif"><o:p></o:p></p></td></tr></table></div><div><div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p></div><div><p class=MsoNormal><span style='font-size:9.0pt;font-family:"Arial","sans-serif";color:#161D26'>Chuck Strand, Chief Executive Officer</span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-size:9.0pt;font-family:"Arial","sans-serif";color:#161D26'>James Hutson, Development Director</span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-size:9.0pt;font-family:"Arial","sans-serif";color:#161D26'>Jackie Konieczka, Office Manager</span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-size:9.0pt;font-family:"Arial","sans-serif";color:#161D26'>Terri Likowski, Program Director - Support Group Services</span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-size:9.0pt;font-family:"Arial","sans-serif";color:#161D26'>Tim Mix, Communications Manager</span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div></div></div></td></tr></table></div></td></tr></table></div><p class=MsoNormal align=center style='text-align:center'><o:p> </o:p></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width: 100%'><tr><td width="100%" valign=top style='width:100.0%;padding:0cm 0cm 0cm 0cm'><div><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width: 100%'><tr><td valign=top style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width: 100%;cursor:default'><tr><td width="100%" valign=top style='width:100.0%;padding:6.75pt 0cm 6.75pt 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="93%" style='width:93.0%;border-collapse:collapse;min-width: 93%'><tr style='height:.75pt'><td style='background:black;padding:0cm 0cm 0cm 0cm;height:.75pt'><div><p class=MsoNormal align=center style='text-align:center;mso-line-height-alt:.75pt'><img border=0 width=5 height=1 id="_x0000_i1031" src="https://imgssl.constantcontact.com/letters/images/sys/S.gif"><o:p></o:p></p></div></td></tr></table></div></td></tr></table></div></td></tr></table></div></td></tr></table></div><p class=MsoNormal align=center style='text-align:center'><o:p> </o:p></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width: 100%'><tr><td width="100%" valign=top style='width:100.0%;background:white;padding:0cm 0cm 0cm 0cm;word-wrap: break-word'><div><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;word-wrap: break-word'><tr><td valign=top style='padding:7.5pt 15.0pt 7.5pt 15.0pt'><div><div><div><p class=MsoNormal align=center style='text-align:center'><span style='font-size:7.5pt;font-family:"Arial","sans-serif";color:#333333'>Connect with Us TOO on Social Media:</span><span style='font-family:"Arial","sans-serif";color:#333333'><o:p></o:p></span></p></div></div></div></td></tr></table></div><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td style='padding:0cm 15.0pt 7.5pt 15.0pt'><div><p class=MsoNormal align=center style='text-align:center'><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS5Eb_W96da_SlBOHvGgJfUHML021xEC3-57F4FRSwopWFGymnCdXFbGHB5yJazHn65tX5oq33f06eJlhsmJt_A980cll2jOCQT3uaogz29KyyicG9cv17gk=&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw=="><span style='text-decoration:none'><img border=0 width=32 id="_x0000_i1032" src="https://imgssl.constantcontact.com/galileo/images/templates/Galileo-SocialMedia/facebook-visit-default.png" alt=Facebook> </span></a><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS5Eb_W96da_S26_EeCxQXleCHbln0cSpYkAprmDR2D8Ai19eNG5IwgKA8s5k-V4FnTA6eniuWEcVBGZolM1g00JOx046p40nFQ==&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw=="><span style='text-decoration:none'><img border=0 width=32 id="_x0000_i1033" src="https://imgssl.constantcontact.com/galileo/images/templates/Galileo-SocialMedia/twitter-visit-default.png" alt=Twitter> </span></a><a href="http://r20.rs6.net/tn.jsp?f=001AZZ2tgJ52midJp1fMInzqG_KYfoyul2XemnDdNgw5wzXZkU3063MS20wifJUTjKSENTUdIPlO3xLPppNEjb5pjLFdvhJVLpOzSbFkqVGqegUkmAZybtUeBEbtdDENJkQ9T6QiLC2ulOZIf6AzXSmTBIKffLFHrmmNDb5g6wdy3k=&c=h1sB3bX_7Bn4G9wwVi66NHLh3C0-OAqlI7OXjmJro2dZ7XU3QJyfKw==&ch=gTKgs-99UV8u-rM3hDsRYG7d1hiofcbonY6rgnq0sHY8NzY7B8thqw=="><span style='text-decoration:none'><img border=0 width=32 id="_x0000_i1034" src="https://imgssl.constantcontact.com/galileo/images/templates/Galileo-SocialMedia/linkedin-visit-default.png" alt=LinkedIn> </span></a><o:p></o:p></p></div></td></tr></table></td></tr></table></div></div></td></tr></table></div></td></tr></table></div></td></tr></table></div></td></tr></table></div></div></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'></td></tr></table><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:white;border-collapse:collapse'><tr><td width="100%" valign=top style='width:100.0%;padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td valign=top style='padding:12.0pt 0cm 12.0pt 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=580 style='width:435.0pt;border-collapse:collapse'><tr><td valign=top style='padding:3.0pt 0cm 3.0pt 0cm'><p class=MsoNormal align=center style='text-align:center'><span class=footer-column><span style='font-size:9.0pt;font-family:"Verdana","sans-serif";color:#5D5D5D'>Us TOO International</span></span><span class=footer-mobile-hidden><span style='font-size:9.0pt;font-family:"Verdana","sans-serif";color:#5D5D5D'> | </span></span><span class=footer-column><span style='font-size:9.0pt;font-family:"Verdana","sans-serif";color:#5D5D5D'>2720 S. River Road, Suite 112</span></span><span class=footer-mobile-hidden><span style='font-size:9.0pt;font-family:"Verdana","sans-serif";color:#5D5D5D'>, </span></span><span class=footer-column><span style='font-size:9.0pt;font-family:"Verdana","sans-serif";color:#5D5D5D'>Des Plaines, IL 60018</span></span><span style='font-size:9.0pt;font-family:"Verdana","sans-serif";color:#5D5D5D'> <o:p></o:p></span></p></td></tr><tr><td valign=top style='padding:7.5pt 0cm 7.5pt 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse'><tr><td valign=top style='padding:3.0pt 0cm 3.0pt 0cm'></td></tr><tr><td valign=top style='padding:3.0pt 0cm 3.0pt 0cm'><p class=MsoNormal align=center style='text-align:center'><span style='font-size:9.0pt;font-family:"Verdana","sans-serif";color:#5D5D5D'><a href="https://visitor.constantcontact.com/do?p=oo&m=001KmuJRjw2oGUBkhostjrpJw%3D&ch=1bc4ebc0-6b5e-11e9-96cd-d4ae527b6fcc&ca=0e0aa404-71d8-40b2-89bd-1a312acae9a5"><span style='color:#5D5D5D'>Update Profile</span></a> | <a href="http://www.constantcontact.com/legal/service-provider?cc=about-service-provider"><span style='color:#5D5D5D'>About our service provider</span></a> <o:p></o:p></span></p></td></tr><tr><td valign=top style='padding:3.0pt 0cm 3.0pt 0cm'><p class=MsoNormal align=center style='text-align:center'><span style='font-size:9.0pt;font-family:"Verdana","sans-serif";color:#5D5D5D'>Sent by <a href="mailto:chucks@ustoo.org"><span style='color:#5D5D5D;text-decoration:none'>chucks@ustoo.org</span></a> <span class=footer-column>in collaboration with</span> <o:p></o:p></span></p></td></tr></table></div></td></tr><tr><td valign=top style='padding:3.0pt 0cm 3.0pt 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=240 style='width:180.0pt;border-collapse:collapse'><tr><td valign=top style='padding:0cm 0cm 2.25pt 7.5pt'><p class=MsoNormal align=center style='text-align:center'><a href="http://www.constantcontact.com/index.jsp?cc=nge&rmc=VF19_3GE"><span style='color:#5D5D5D;text-decoration:none'><img border=0 width=211 id="_x0000_i1035" src="https://imgssl.constantcontact.com/ui/images1/logo_ctct_2x.png" alt="Trusted Email from Constant Contact - Try it FREE today."></span></a><o:p></o:p></p></td></tr><tr><td valign=top style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal align=center style='text-align:center'><span style='font-size:7.0pt;font-family:"Verdana","sans-serif";color:#5D5D5D'><a href="http://www.constantcontact.com/index.jsp?cc=nge&rmc=VF19_3GE"><span style='color:#5D5D5D;text-decoration:none'>Try email marketing for free today!</span></a> <o:p></o:p></span></p></td></tr></table></div></td></tr></table></div></td></tr></table></div></td></tr></table><p class=MsoNormal><o:p> </o:p></p></div></body></html>